Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Zuclopenthixol and clozapine-induced neutropenia.

Created on 21 Aug 2026

Authors

Charlie Price, Aisling Reid, Bhaskar Prabhu

Published in

BMJ case reports. Volume 19. Issue 8. Aug 20, 2026. Epub Aug 20, 2026.

Abstract

We highlight a case of zuclopenthixol-induced neutropenia, a rarely reported adverse effect (AE), and subsequent susceptibility to clozapine-induced neutropenia. Neutropenia is an uncommon but clinically significant haematological AE associated with several psychotropic agents, most notably clozapine.We describe a man in his 30s with treatment-resistant schizophrenia who developed medication-induced neutropenia during treatment with both zuclopenthixol and clozapine. Baseline absolute neutrophil count (ANC) was normal (3.16×10⁹/L). During oral zuclopenthixol therapy, the patient developed neutropenia (1.29×10⁹/L) and eosinophilia. ANC normalised following drug discontinuation.Clozapine was subsequently initiated with a cautious titration; however, neutropenia reoccurred (1.31×10⁹/L), with a persistently reduced ANC for 15 days after cessation. Investigations excluded infective, autoimmune, nutritional and primary haematological causes.The patient was subsequently established on amisulpride and lithium, with recovery of ANC. This case highlights the potential susceptibility to antipsychotic-induced neutropenia and the consideration of lithium for augmentation of ANC in future therapy.

PMID:
42624624
Bibliographic data and abstract were imported from PubMed on 21 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement